ArticleEndocrine, metabolic & immune disorders drug targets2026
Construction of a Single-cell Atlas of Thyroid Cancer
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDifferentiated thyroid cancer generally has a favorable prognosis; however, the cure rate remains low for patients with metastatic or undifferentiated thyroid cancer. Moreover, this group of patients exhibits diverse responses to different treatments. To address this, single- cell RNA sequencing (scRNA-seq) offers an unbiased approach to reveal the heterogeneity within and between tumor cells. Using, scRNA-seq, we aimed to explore the intricate ecosystem of thyroid cancer, potentially providing novel insights into clinical cancer staging and treatment strategies.
methodsWe conducted a thorough analysis by screening thyroid cancer and paraneoplastic tissues from 20 patients sourced from the Gene Expression Omnibus database. The dataset comprised 11 primary tumor tissues, 6 paraneoplastic tissues, 8 metastatic lymph nodes, and 2 distant metastases of papillary thyroid cancer. Through comprehensive bioinformatic analyses, we constructed a panoramic single-cell atlas of thyroid cancer (THCA).
resultsOur findings revealed significant heterogeneity in gene expression among tumor cells from different patients with THCA, contributing to the development of a comprehensive single- cell landscape. Notably, the long noncoding RNA (lncRNA) gene XIST exhibited higher abundance in anaplastic thyroid cancer (ATC) tumor cells. Additionally, we identified an enriched m6A locus in lncRNA XIST and observed high expression of the m6A “reader” IGF2BP3, as well as low expression of the “encoder” VIRMA. Based on these observations, we hypothesized that IGF2BP3 and VIRMA could augment the expression of lncRNA XIST, thereby promoting the malignant proliferation and invasion of ATC.
conclusionBy leveraging scRNA-seq technology, our study sheds light on the intricate molecular characteristics of THCA lesions. These findings have the potential to revolutionize our understanding of thyroid cancer pathogenesis and pave the way for innovative therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.